{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:14:53Z","timestamp":1791317693016,"version":"4.3.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Neurana Pharmaceuticals, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1111\/jcpt.13165","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T05:34:17Z","timestamp":1589175257000},"page":"774-782","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine"],"prefix":"10.1155","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-2971","authenticated-orcid":false,"given":"Judy","family":"Caron","sequence":"first","affiliation":[{"name":"Neurana Pharmaceuticals, Inc. San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-7287","authenticated-orcid":false,"given":"Randall","family":"Kaye","sequence":"additional","affiliation":[{"name":"Neurana Pharmaceuticals, Inc. San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wessel","sequence":"additional","affiliation":[{"name":"Neurana Pharmaceuticals, Inc. San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Halseth","sequence":"additional","affiliation":[{"name":"Neurana Pharmaceuticals, Inc. San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kay","sequence":"additional","affiliation":[{"name":"Drug Development Cognitive Research Corporation St. Petersburg FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-7-200710020-00006"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3463"},{"key":"e_1_2_7_4_1","first-page":"427","article-title":"Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain","volume":"39","author":"Witenko C","year":"2014","journal-title":"Pharm Ther"},{"key":"e_1_2_7_5_1","unstructured":"US Food and Drug Administration.FDA Drug Safety Communication: FDA strengthens warning that non\u2010aspirin nonsteroidal anti\u2010inflammatory drugs (NSAIDS) can cause heart attacks or strokes. Available at:https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010fda\u2010strengthens\u2010warning\u2010non\u2010aspirin\u2010nonsteroidal\u2010anti\u2010inflammatory. Published July 9 2015. Accessed January 31 2020."},{"key":"e_1_2_7_6_1","unstructured":"Drug Enforcement Administration.Cyclobenzaprine (Brand Name: Flexeril\u00ae Amrix\u00ae). Available at:https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/cyclobenzaprine.pdf. Published July 2019. Accessed January 21 2020."},{"key":"e_1_2_7_7_1","unstructured":"US Food and Drug Administration.Guidance document. Evaluating drug effects on the ability to operate a motor vehicle. Available at:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/evaluating\u2010drug\u2010effects\u2010ability\u2010operate\u2010motor\u2010vehicle. Published November 2017. Accessed January 21 2020."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-7-200910060-00005"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014520882"},{"key":"e_1_2_7_10_1","first-page":"768","article-title":"A human subject study of sedative effects of medications in combination with alcohol","volume":"21","author":"Kohnen R","year":"1995","journal-title":"Psycho"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2012.683118"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(96)03187-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01006.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.01.005"},{"key":"e_1_2_7_15_1","unstructured":"European Medicines Agency.Assessment report for tolperisone\u2010containing medicinal products. Procedure number: EMEA\/H\/A\u201031\/1311. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/referral\/assessment\u2010report\u2010tolperisone\u2010containing\u2010medicinal\u2010products_en.pdf. Published January 21 2013. Accessed January 21 2020."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979315"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.4184\/asj.2012.6.2.115"},{"key":"e_1_2_7_18_1","first-page":"33","article-title":"A phase IV observational multi\u2010centre, open\u2010label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system","volume":"59","author":"Prabhoo R","year":"2011","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2603"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2530"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615579314"},{"key":"e_1_2_7_22_1","first-page":"22","article-title":"Effects of lasmiditan on driving performance: results of 2 randomized, blinded, crossover simulated driving studies with placebo and active controls [abstract IOR06]","volume":"59","author":"Pearlman EM","year":"2019","journal-title":"Headache"},{"key":"e_1_2_7_23_1","unstructured":"Statistics Solutions.Wechsler Adult Intelligence Scale\u2014Fourth Edition (WAIS\u2013IV). Available at:https:\/\/www.statisticssolutions.com\/wechsler\u2010adult\u2010intelligence\u2010scale\u2010fourth\u2010edition\u2010wais\u2010iv. Accessed January 31 2020."},{"key":"e_1_2_7_24_1","volume-title":"Driver characteristics and impairment at various BACs (DOT HS 809 075)","author":"Moskowitz H","year":"2000"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","unstructured":"KayG AhmadO BrownT VeitA.Comparison of the MiniSim and STISIM driving simulators for the detection of impairment: an alcohol validation study. Proceedings of the Seventh International Driving Symposium on Human Factors in Driver Assessment Training and Vehicle Design.2013. Available at:https:\/\/ir.uiowa.edu\/cgi\/viewcontent.cgi?article=1487&context=drivingassessment. Accessed January 21 2020.","DOI":"10.17077\/drivingassessment.1487"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5384"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","unstructured":"KayGG LoganBK.Drugged driving expert panel report: a consensus protocol for assessing the potential of drugs to impair driving.2011. Available at:https:\/\/www.nhtsa.gov\/sites\/nhtsa.dot.gov\/files\/811438.pdf. Accessed January 21 2020.","DOI":"10.1037\/e729092011-001"},{"key":"e_1_2_7_28_1","unstructured":"LeRoyAA MorseML.Department of Transportation. HS 810 858.Multiple medications and vehicle crashes: analysis of databases.2008. Available at:http:\/\/www.nhtsa.gov\/DOT\/NHTSA\/Traffic%20Injury%20Control\/Articles\/Associated%20Files\/810858.pdf. Accessed January 31 2020."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P628"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.13165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jcpt.13165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:01Z","timestamp":1671818701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.13165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/jcpt.13165"],"URL":"https:\/\/doi.org\/10.1111\/jcpt.13165","archive":["Portico"],"relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,10]]},"assertion":[{"value":"2020-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}